LOS ANGELES--(BUSINESS WIRE)--Glancy Binkow & Goldberg LLP announces that it is investigating potential claims on behalf of investors of Nu Skin Enterprises, Inc. (“Nu Skin” or the “Company”) (NYSE:NUS) concerning possible violations of federal securities laws. The investigation is focused on certain statements issued by Nu Skin concerning the Company’s operations.
Please contact us at (212) 682-5340, Toll-Free at (888) 773-9224, or at firstname.lastname@example.org to discuss this matter. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
The investigation is related to news reports alleging that the Company distributes false information and conducts illegal business in China. On January 15, 2014, China’s Communist Party newspaper, The People's Daily, alleged that Nu Skin had been misrepresenting its influence and creditworthiness in Company brochures, and passing advertisements as news reports. The newspaper subsequently alleged that the Company was suspected of conducting illegal multi-level marketing activities in China. Following this news, on January 15, 2014, the price of Nu Skin shares dropped $21.24 per share, on heavy trading volume, to a closing price of $115.23 per share. On January 16, 2014, China’s state news agency, Xinhua, said China's State Administration for Industry and Commerce had ordered local authorities to investigate the recent media reports about Nu Skin.
If you purchased Nu Skin shares, if you have information or would like to learn more about these claims, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll-Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to email@example.com, or visit our website at http://www.glancylaw.com. If you inquire by email, please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.